Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.81 CAD -3.21%
Market Cap: 147.7m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note

Cardiol Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiol Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Research & Development
-CA$13.8m
CAGR 3-Years
2%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Research & Development
-CA$324k
CAGR 3-Years
13%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Research & Development
-$4.7m
CAGR 3-Years
42%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Research & Development
-$53.7m
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
-120%
C
Curaleaf Holdings Inc
CNSX:CURA
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
147.7m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Research & Development?
Research & Development
-13.8m CAD

Based on the financial report for Sep 30, 2024, Cardiol Therapeutics Inc's Research & Development amounts to -13.8m CAD.

What is Cardiol Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-38%

Over the last year, the Research & Development growth was 13%. The average annual Research & Development growth rates for Cardiol Therapeutics Inc have been 2% over the past three years , -38% over the past five years .

Back to Top